-
Beta-Blockers Therapy for the Treatment of Hypertension; Treatments for Acute Migraine; Statin Therapy for ACS Patients; The Correct Dosing for Onychomycosis; FDA Actions
-
I missed this article when it first emerged. however, during a recent perinatal conference in California, Dr. Michael Nageotte cited it in an excellent lecture on breeches. Since the report could have an impact in current practice, I am reviewing it in this issue.
-
A surprising study recently surfaced in the British Medical Journal. A randomized trial was designed to determine if giving a standard maternal dose of steroids (two injections of 12 mg of betamethasone separated by 24 hours) would decrease the incidence of respiratory distress syndrome (RDS) in infants whose mothers were to have elective Cesarean sections.
-
E3N is a French prospective study of cancer risk factorsEtude Epidémiologique de femmes de la Mutuelle Générale de lEduction National. The study population, after exclusions, consists of 54,548 women born between 1925 and 1950, and all belong to a health insurance program that primarily covers teachers.
-
-
Population-based ovarian cancer screening programs have been difficult to recommend and implement because poor sensitivity and positive predictive value characteristics accompany expensive and inefficient testing methodology and triage algorithms.
-
Ogburn and colleagues report on their experience with adnexal torsion at one university medical center from 1990 to 2001. A chart review identified 68 patients in whom laparoscopic management was accomplished 32% of the time (n = 22) and ovarian conservation in 21% (n = 14).
-
A new combination hormone product has been approved for the treatment of menopausal symptoms. Drospirenone (DRSP), a progestin with mineralo-corticoid activity, is combined with estradiol (E2). DRSP is the same progestin found in the popular oral contraceptive, Yasmin®. DRSP-E2 is marketed by Berlex as Angeliq®.
-
Endometrial cancer is the most common gynecologic malignancy and is usually characterized by limited disease at presentation. Among the number of known prognostic factors, grade of disease is one frequently used to triage patients for formal surgical staging.
-
Souka and colleagues have recently published a review that should be very helpful to the clinician confronted with the dilemma of counseling patients whose fetuses have increased nuchal translucencies (NTs) in the first trimester.
